Advance Search
Volume 41 Issue 6
Jun.  2020
Turn off MathJax
Article Contents
Abstract
References
ZHI Jia, LI Dongning, ZHENG Song, YANG Yang, ZHAO Fengmei. Expressions of PD-1/PD-L1 in tissues of Bowen's disease and cutaneous squamous cell carcinoma[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2020, 41(6): 628-633. DOI: 10.3969/j.issn.2095-5227.2020.06.018
Citation: ZHI Jia, LI Dongning, ZHENG Song, YANG Yang, ZHAO Fengmei. Expressions of PD-1/PD-L1 in tissues of Bowen's disease and cutaneous squamous cell carcinoma[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2020, 41(6): 628-633. DOI: 10.3969/j.issn.2095-5227.2020.06.018
shu

Expressions of PD-1/PD-L1 in tissues of Bowen's disease and cutaneous squamous cell carcinoma

  • 1.

    Department of Dermatology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, Liaoning Province, China

  • 2.

    Department of Dermatology, the First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

  • 3.

    Department of Dermatology, Fushun Mining Bureau General Hospital of Liaoning Health Industry Group, Fushun 113008, Liaoning Province, China

More Information
    Graphical Abstract
    • Abstract
  •   Objective  To investigate the expressions of PD-1 and PD-L1 in tissues of Bowen's disease and cutaneous squamous cell carcinoma (cSCC), and analyze their relationships with the tumor differentiation, depth of invasiveness and other clinicopathological characteristics.
      Methods  Skin biopsy specimens of 49 cases of Bowen's disease, 47 cases of highly differentiated cSCC and 25 cases of poorly differentiated cSCC were retrieved, and immunohistochemical stains for PD-1 and PD-L1 in the three groups of samples were performed. Image-pro Plus was used to analyze the average optical density value and data were compared between the three groups.
      Results  Tumor infiltrating cells, instead of tumor cells, expressed PD-1 and PD-L1. The expression levels of PD-1 and PD-L1 were higher in the poorly differentiated cSCC than those in the highly differentiated cSCC (P < 0.001, respectively), and they were also higher in the highly differentiated cSCC than in Bowen's disease (P < 0.01, respectively). PD-L1 expressed significantly higher in deeper cSCC than in superficial cSCC (P < 0.01), while PD-1 showed no significant difference between the two groups(P > 0.05). There was no statistically significant difference in the expressions of PD-1 and PD-L1 in Bowen's disease and cSCC tissues of different genders, ages, races, tumor locations, disease durations and tumor diameters (all P > 0.05).
      Conclusion  The expression of PD-1 and PD-L1 is correlated with the differentiation of cSCC, and the expression of PD-L1 is correlated with the depth of invasiveness of cSCC.
    • FullText(HTML)
    • References (21)
  • [1]
    Burton KA, Ashack KA, Khachemoune A. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease[J]. Am J Clin Dermatol, 2016, 17(5): 491-508. doi: 10.1007/s40257-016-0207-3
    [2]
    Quatresooz P, Piérard-Franchimont C, Paquet P, et al. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues[J]. Eur J Dermatol, 2008, 18(1): 6-10.
    [3]
    Chong K, Daud A, Ortiz-Urda S, et al. Cutting edge in medical management of cutaneous oncology[J]. Semin Cutan Med Surg, 2012, 31(2): 140-149. doi: 10.1016/j.sder.2012.03.002
    [4]
    Zhao T, Li C, Wu Y, et al. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis[J]. PLoS One, 2017, 12(4): e0176822. doi: 10.1371/journal.pone.0176822
    [5]
    Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes[J]. Onco Targets Ther, 2016, 9: 5023-5039. doi: 10.2147/OTT.S105862
    [6]
    Zerdes I, Matikas A, Bergh J, et al. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations[J]. Oncogene, 2018, 37(34): 4639-4661. doi: 10.1038/s41388-018-0303-3
    [7]
    Wang A, Wang HY, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis[J]. Eur J Surg Oncol, 2015, 41(4): 450-456. doi: 10.1016/j.ejso.2015.01.020
    [8]
    Feldman R, Gatalica Z, Knezetic J, et al. Molecular profiling of head and neck squamous cell carcinoma[J]. Head Neck, 2016, 38 Suppl 1(Suppl 1): E1625-E1638.
    [9]
    Koh J, Go H, Keam B, et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status[J]. Mod Pathol, 2015, 28(9): 1154-1166. doi: 10.1038/modpathol.2015.63
    [10]
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264. doi: 10.1038/nrc3239
    [11]
    Kang MJ, Kim KM, Bae JS, et al. Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma[J]. Transl Oncol, 2013, 6(3): 282-289. doi: 10.1593/tlo.13256
    [12]
    Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma[J]. Clin Ther, 2015, 37(4): 764-782. doi: 10.1016/j.clinthera.2015.02.018
    [13]
    Sun S, Fei X, Mao Y, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients[J]. Cancer Immunol Immunother, 2014, 63(4): 395-406. doi: 10.1007/s00262-014-1519-x
    [14]
    Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma[J]. Clin Cancer Res, 2009, 15(20): 6341-6347. doi: 10.1158/1078-0432.CCR-09-1652
    [15]
    Zhao Q, Xiao X, Wu Y, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients[J]. Eur J Immunol, 2011, 41(8): 2314-2322. doi: 10.1002/eji.201041282
    [16]
    Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis[J]. J Cutan Pathol, 2016, 43(8): 663-670. doi: 10.1111/cup.12728
    [17]
    Pitt JM, Vétizou M, Daillère R, et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors[J]. Immunity, 2016, 44(6): 1255-1269. doi: 10.1016/j.immuni.2016.06.001
    [18]
    Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition[J]. Crit Rev Oncol Hematol, 2017, 116: 116-124. doi: 10.1016/j.critrevonc.2017.06.001
    [19]
    Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions[J]. Cancer Immunol Immunother, 2017, 66(5): 551-564. doi: 10.1007/s00262-017-1954-6
    [20]
    Berger KN, Pu JJ. PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene[J]. Gene, 2018, 638: 20-25. doi: 10.1016/j.gene.2017.09.050
    [21]
    Degache E, Crochet J, Simon N, et al. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma[J]. J Eur Acad Dermatol Venereol, 2018, 32(7): e257-e258. doi: 10.1111/jdv.14371
    • Related Articles

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (877) PDF downloads (14) Cited by()
    Related
    Contact Us
    • Phone：(010)66936767
    • Email： xuebao301@vip.163.com
    • Address：PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, China
    Download Center
    Links

    Copyright © Editorial Department of Journal of PLA Medical College 京ICP备17052889号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return